Celltrion Announces the Acquisition of iQone Healthcare Switzerland, Further Building Its Expertise and Foothold in Europe

Contributed by: Business Wire

Logo

Tags

Biotechnology

General Health

Health

Pharmaceutical

Managed Care

biosimilars

More Like This

Zymfentra® (Photo: Celltrion)

Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger

Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe

Celltrion opens new UK headquarters in Uxbridge, UK

Celltrion opens new UK headquarters in Uxbridge, UK

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

BeOne Medicines' biologics manufacturing facility and clinical R&D center in Hopewell, NJ.

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation

Photo of ion trap (Image courtesy of IonQ)

IonQ Delivers First Overseas Ion Trap to Switzerland, Progressing Development of Quantum Innovation Hub for EMEA

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union